Lyndra Therapeutics
Total Raised
$273.39MInvestors Count
21Deal Terms
2Funding, Valuation & Revenue
9 Fundings
Lyndra Therapeutics has raised $273.39M over 9 rounds.
Lyndra Therapeutics's latest funding round was a Series E for $101M on December 21, 2023.
Lyndra Therapeutics's latest post-money valuation is from December 2023.
Sign up for a free demo to see Lyndra Therapeutics's valuations in December 2023 and more.
Lyndra Therapeutics's 2022 revenue was $10.7M. Lyndra Therapeutics's most recent revenue is from 2020.
Sign up for a free demo to see revenue data from 2021, 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/21/2023 | Series E | $101M | 4 | |||
6/7/2023 | Series D | $10.7M (29.4x) FY 2022 | ||||
6/24/2021 | Series C | |||||
7/30/2019 | Grant - III | |||||
1/28/2019 | Series B |
Date | 12/21/2023 | 6/7/2023 | 6/24/2021 | 7/30/2019 | 1/28/2019 |
|---|---|---|---|---|---|
Round | Series E | Series D | Series C | Grant - III | Series B |
Amount | $101M | ||||
Investors | |||||
Valuation | |||||
Revenue | $10.7M (29.4x) FY 2022 | ||||
Sources | 4 |
Lyndra Therapeutics Deal Terms
2 Deal Terms
Lyndra Therapeutics's deal structure is available for 2 funding rounds, including their Series E from December 21, 2023.
Round | Series E | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series E | |||||||||||||||
Series A |
Lyndra Therapeutics Investors
21 Investors
Lyndra Therapeutics has 21 investors. Polaris Partners invested in Lyndra Therapeutics's Series E funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/5/2015 | 12/21/2023 | 6 Seed VC, Series A (2016), Series B (2019), Series C (2021), Series D (2023), Series E (2023) | Venture Capital | Massachusetts | ||
12/21/2023 | 12/21/2023 | 1 Series E | Corporation | India | ||
12/21/2023 | 12/21/2023 | 1 Series E | Asset/Investment Management | Connecticut | ||
Venture Capital | Canada | |||||
Asset/Investment Management | New York |
First funding | 8/5/2015 | 12/21/2023 | 12/21/2023 | ||
|---|---|---|---|---|---|
Last Funding | 12/21/2023 | 12/21/2023 | 12/21/2023 | ||
Investor | |||||
Rounds | 6 Seed VC, Series A (2016), Series B (2019), Series C (2021), Series D (2023), Series E (2023) | 1 Series E | 1 Series E | ||
Board Seats | |||||
Type | Venture Capital | Corporation | Asset/Investment Management | Venture Capital | Asset/Investment Management |
Location | Massachusetts | India | Connecticut | Canada | New York |
Compare Lyndra Therapeutics to Competitors
FierceHealthcare reports on business news and analysis within the healthcare industry. The company provides information on healthcare providers, payers, technology innovators, and other key players in the sector, focusing on news, policy updates, and industry trends. FierceHealthcare has an audience that includes executives in healthcare, technology, finance, and regulatory sectors. It was founded in 2006 and is based in New York, New York. FierceHealthcare operates as a subsidiary of Questex Media Group.
SmartTab focuses on the integration of advanced medicines with wireless technology, operating within the healthcare and technology sectors. The company's main offering is a wireless drug delivery platform, which includes ingestible capsules that can deliver medication to targeted areas within the body, such as the stomach, intestines, and colon. These capsules can also connect to smart devices via Bluetooth to monitor therapy optimization. The company primarily serves the healthcare industry. SmartTab was formerly known as Velóce Digital Health. It was founded in 2015 and is based in Denver, Colorado.
Rani Therapeutics is a clinical-stage biotech company focused on the oral delivery of biologics within the pharmaceutical industry. The company has developed the RaniPill platform, which is designed to replace traditional injections of biologic drugs with an oral pill that delivers the medication to the intestinal wall. This technology provides an alternative to injections for patients with chronic conditions. It was founded in 2012 and is based in San Jose, California.
Biora Therapeutics develops smart-pill technologies within the healthcare sector. The company focuses on needle-free, oral delivery systems for large molecules, related to the management of chronic diseases and drug delivery to the gastrointestinal tract. Biora Therapeutics serves the pharmaceutical and biotechnology industries with its investigational platforms. It is based in San Diego, California.
Loading...